

Comparative Landscape Report

Disease: Melanoma

Products Analyzed: 1

Total Patents: 1

Total Clinical Trials: 1

1. Portfolio Overview

Product Name	Phase	Target Indication	Description
Pembrolizumab	Approved	Melanoma; NSCLC; TNBC	Synthetic data for pembrolizumab.

3. Comparitive Clinical Status

Phase 3

Product	Status	Trial Title
Pembrolizumab	Completed	KEYNOTE-189: Pemetrexed/Platinum with or without Pembrolizumab in NSCLC